Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
These results highlight that injectables generally deliver the greatest effect, while oral tablets and daily injections provide moderate but still meaningful reductions
The various DPP-4 inhibitors do not form a homogenous class of molecules, and they show different interactions with the active site of the enzyme molecule
GLP-1 Drug Market Research Report: Size, Share, Trend Analysis By Drug Type (Short-acting, Long-acting, Dual-action), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Type 2 Diabetes, Obesity, Cardiovascular Diseases), By Administration Route (Subcutaneous Injection, Oral, Inhalation) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035 ID: MRFR/HC/20411-HCR 128 Pages Last Updated: May 15, 2026 GLP-1 Drug Market Market Size Forecast Period2025 - 2035 CAGR (2025 - 2035)13.17% 2024 Market Size$ 10.77 Billion 2025 Market Size$ 12.19 Billion 2035 Market Size$ 42 Billion Key Players Companies such as Novo Nordisk Eli Lilly Sanofi Boehringer Ingelheim AstraZeneca Merck & Co
Built for Researchers Clear documentation, batch-specific COAs, fast fulfillment
Now, with millions of people taking semaglutide and tirzepatide worldwide, the signal has become impossible to ignore
Main clinical scenarios where injections are essential Injections are essential when absorption is impaired
